FDA-Approved Treatments for Alzheimer’s Disease

Learning Objectives

  1. Review 1st generation FDA-approved treatments for dementia due to Alzheimer’s disease.
  2. Summarize status of new, 2nd generation FDA-approved medications for mild cognitive impairment or mild dementia due to Alzheimer’s disease.

Pierre Tariot, MD

Dr. Tariot is Board Certified in Internal Medicine and Psychiatry with added qualifications in geriatrics.  He was as a Fellow at the National Institute of Mental Health (NIMH) Intramural Research Program, then served as a faculty member at the University of Rochester Medical Center and, since 2006, he has served as Director of the Banner Alzheimer’s Institute in Phoenix. He is also a Research Professor of Psychiatry at the University of Arizona College of Medicine. His work has focused on care and study of people with and at risk for Alzheimer’s, with emphasis on design and implementation of clinical trials for prevention and treatment, development of biomarkers, characterization and treatment of neuropsychiatric features of dementia, and demonstration of effective dementia care. He has published over 450 papers on these topics including those regarding studies that have led to FDA approval of new medications. He serves as co-director of the international Alzheimer’s Prevention Initiative (API). His research affiliations include the National Institute on Aging (NIA), the NIMH, and the Alzheimer’s Association and he is a Fellow of the American College of Neuropsychopharmacology.